Molecular Formula | C12H15IO2 |
Molar Mass | 318.15 |
Density | 1.547±0.06 g/cm3(Predicted) |
Boling Point | 369.6±27.0 °C(Predicted) |
pKa | 4.32±0.11(Predicted) |
Storage Condition | -20℃ |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 3.143 ml | 15.716 ml | 31.432 ml |
5 mM | 0.629 ml | 3.143 ml | 6.286 ml |
10 mM | 0.314 ml | 1.572 ml | 3.143 ml |
5 mM | 0.063 ml | 0.314 ml | 0.629 ml |
Background | Alecensa(alectinib) alectinib (aratinib) for the treatment of Xalkori (crizotinib) patients with advanced (metastatic) ALK-positive non-small cell lung cancer (NSCLC) who have deteriorated after treatment or cannot tolerate crizotinib therapy. |
Application | , in the synthesis of new drugs has important research value, broad market and good prospects for development.